GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NuGel overview
NuGel (sodium taurodeoxycholic acid) is under development for the treatment of atopic dermatitis and sepsis. The drug is composed of sodium taurodeoxycholate. It is administered through transdermal route as gel formulation. It acts by targeting the GPCR19.
Shaperon overview
Shaperon is a biopharmaceutical development company that is engaged in research and development of pneumonia therapy and alzheimer’s disease therapy. The company is headquartered in Seoul, South Korea.
For a complete picture of NuGel’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#NuGel #Shaperon #Sepsis #Likelihood #Approval
